News

Allay Therapeutics Enhances Advisory Boards for Pain Management

Allay Therapeutics Enhances Advisory Boards for Pain Management

Allay Therapeutics Strengthens Advisory Boards

Allay Therapeutics, a clinical-stage biotechnology company specializing in innovative pain management solutions, has announced an exciting expansion of its Clinical and Scientific Advisory Boards. This move aims to bolster the company’s capabilities as it focuses on advancing ATX101, a promising clinical candidate designed to transform post-surgical pain relief.

Expanding Expertise in Pain Management

In its commitment to revolutionize post-surgical pain management, Allay Therapeutics has appointed nine distinguished experts in the fields of pain management, pharmacology, anesthesiology, and clinical research to provide strategic insights. These leaders will guide the company as it navigates the complexities of clinical trials and regulatory processes while embarking on a significant Phase 2B registration trial for ATX101.

Composition of the Advisory Boards

Allay’s expanded Clinical Advisory Board (CAB) includes renowned members such as Sabry Ayad, M.D., a professor known for his extensive work in anesthesiology; Ron Burch, M.D., Ph.D., who brings a wealth of experience from senior positions in biopharmaceutical companies; David Dalury, M.D., an orthopedic surgeon focused on knee and hip surgeries; Hemant Pandit, FRCS, D.Phil, an expert in arthroplasty and research; and Christine Sang, M.D., M.P.H., recognized for her leadership in anesthesia and pain research.

The Scientific Advisory Board (SAB) sees contributions from leading minds like Christine Allen, Ph.D., noted for her advancements in drug formulation; Joachim Kohn, Ph.D., who specializes in developing biomedical products; Louis Lazo Radulovic, Ph.D., M.P.H., an authority in pharmacokinetics; and Arthur Tipton, Ph.D., a pioneer of drug delivery innovations.

Insights from Leadership

Adam Gridley, Chief Executive Officer of Allay Therapeutics, emphasized the importance of these appointments: "We are thrilled to welcome such a talented group of physicians and scientists to our expanded boards. Their diverse experiences will offer valuable guidance as we work to bring our ultra-sustained analgesic, ATX101, to market." The expertise of these advisors will be pivotal in addressing the challenges of the clinical landscape and ensuring patient needs are met effectively.

Understanding ATX101

ATX101 is a novel investigational product utilizing bupivacaine, coupled with a biopolymer to provide prolonged pain relief following surgeries such as total knee arthroplasty. Its unique formulation allows for the delivery of sustained analgesic effects over several weeks, significantly enhancing patient recovery experiences. The simplicity of its application during surgery demands no specialized training, positioning it as a groundbreaking alternative to conventional pain management methods.

About Allay Therapeutics

Allay Therapeutics is dedicated to advancing pain management through innovative technologies. Its proprietary platform integrates validated non-opioid analgesics and biopolymers to create dissolvable solutions that offer targeted, long-lasting pain relief. With a passionate team in the San Francisco Bay Area and Singapore, Allay aims to redefine post-surgical recovery and improve the overall quality of life for patients worldwide.

Frequently Asked Questions

What is the focus of Allay Therapeutics?

Allay Therapeutics specializes in developing innovative pain management solutions, particularly through the drug candidate ATX101.

Who are the new members of the advisory boards?

Allay has appointed experts in pain management, orthopedics, drug delivery, and pharmacology to its Clinical and Scientific Advisory Boards.

What is ATX101?

ATX101 is a novel investigational product designed to provide weeks of pain relief after surgeries like knee replacements.

How does Allay plan to develop ATX101?

Allay is advancing ATX101 through clinical trials, particularly a Phase 2B registration trial, leveraging insights from its expanded advisory boards.

What is the vision of Allay Therapeutics?

Allay seeks to transform post-surgical pain management by providing long-lasting, effective, and non-opioid pain relief options for patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Minnesota Giving Record Signals a Stressed Safety Net

Updated Category News Views 63

Thirty-eight million dollars landing in one day is no small civic heartbeat. Minnesota’s Give to the Max Day brought in a record $38.4 million in 2026 for nearly 6,000 nonprofits and schools, edging past the $37.8 million raised in 2025. More than 65,000 people gave. That deserves a clear-eyed nod, not a cynical shrug. Still, the number carries two messages at once. It...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 27

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 79

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 123

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 61

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Ampace Targets AI Data Centre UPS Safety Needs in Paris

Updated Category News Views 109

Backup power gets interesting only after the grid has disappointed everybody. At Data Centre World Paris 2026, Ampace put its attention on that ugly, split-second handoff: utility power drops, a UPS has to catch the load immediately, and nobody operating an AI data centre gets to shrug if it does not. A Narrow Job With Brutal Consequences The company showcased its PU200...

Continue Reading
ADFW 2026 Builds a Bigger Stage for Global Capital

Updated Category News Views 30

Abu Dhabi is not merely booking conference rooms this December; it is assembling a very deliberate display of financial muscle. Abu Dhabi Finance Week runs from 7 to 10 December 2026, and ADGM says its fifth edition will carry its largest-ever programme of partner-led activity. That is a promotional claim, sure, but the partner list is substantial enough that investors...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 119

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Straub's Court Win Raises Cost of Seven-Year Fight

Updated Category News Views 68

Seven years of courtroom smoke over an under-$80,000 lien is the sort of mess that makes any business owner grind his teeth. Palm Beach Polo says its president, Glenn Straub, has again prevailed against Jessica Nicodemo in Palm Beach County, following an earlier Broward County dismissal of related claims. The company also says Vice President Sal Spano received a directed...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading